Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00370 ...
Drug Name Mirtazapine
Molecular Weight 265.3529
Molecular Formula C17H19N3
CAS Number 85650-52-8
SMILES CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
External Links
DRUGBANK DB00370
T3DB T3D2767
PubChem Compound 4205
PDR 3335
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 2.9 - 2.9 - http://sitem.herts.ac.uk/aeru/vsdb/Reports/2980.htm
Boiling Point 432.4 ℃ 432.4 ℃ https://www.lookchem.com/Mirtazapine/
Melting Point 115.0 ℃ 114-116 ℃ https://www.chemicalbook.com/ChemicalProductProperty_US_CB0463388.aspx
pKa 7.7 - 7.7 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2825368/

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % 100.0 % PO, oral; food; food → ; DRUGBANK
Bioavailability 50.0 % 50.0 % PO, oral; food; food → ; DRUGBANK
Bioavailability 50.0 % 50±10 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 41.8 ng/ml 41.8±7.7 ng/ml PO, oral; The Pharmacological Basis of Therapeutics
T Max 2.0 h 2 h PO, oral; food; food → ; DRUGBANK
T Max 1.5 h 1.5±0.7 h PO, oral; The Pharmacological Basis of Therapeutics
Tss 120.0 h 5.0 day PO, oral; DRUGBANK
Clearance 31.0 L/h 31.0 L/h Total clearance; intravenous injection, IV; Male, men; hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;Age ↓ ; DRUGBANK
Clearance 0.55 L/h/kg 9.12±1.14 ml/min/kg normal,healthy; adults; hydrolysis; hydrolysis; hydrolysis; hepatopathy，LD ↓ ;moderate renal function ↓ ;severe renal function ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.48 L/h/kg 8 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 107.0 L 107±42 L PO, oral; DRUGBANK
Volume of Distribution 4.5 L/kg 4.5±1.7 L/kg normal,healthy; adults; hydrolysis; hydrolysis; hydrolysis; The Pharmacological Basis of Therapeutics
Volume of Distribution 4.2 L/kg 4.2 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 30.0 h 20-40 h DRUGBANK
Half-life 16.3 h 16.3±4.6 h chronic liver disease ↑ ;moderate renal function ↑ ;severe renal function ↑ ; The Pharmacological Basis of Therapeutics
Half-life 15.0 h 15 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 830.0 mg/kg 830.0 mg/kg PO, oral; Male, men; mouse; DRUGBANK
Toxicity LD50 660.0 mg/kg 600-720 mg/kg PO, oral; mouse; T3DB
Toxicity LD50 405.0 mg/kg 320-490 mg/kg PO, oral; Rattus, Rat; T3DB
Eliminate Route 75.0 % 75 % Urinary excretion; DRUGBANK
Eliminate Route 15.0 % 15 % Faeces excretion; DRUGBANK
Protein Binding 85.0 % ~85 % plasma proteins; DRUGBANK
Protein Binding 85.0 % 85 % adults; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 45.0 mg/day 45 mg/day PO, oral Mirtazapine mirtazapine PDR
Max dose for geriatric 45.0 mg/day 45 mg/day PO, oral Mirtazapine mirtazapine PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1